Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 23, 2014
Pharmacy Choice - News - Pharmaceutical Development - July 23, 2014

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 234     Next >>     Go To Page:

7/23/14 - A collection of approx..1100 FDA approved drugs in pre-dissolved 100ul of DMSO solution for high throughput screening (HTS) and high content... [TendersInfo (India)]
A collection of approx.. 1100 FDA approved drugs in pre-dissolved 100 ul of DMSO solution for high throughput screening and high content screening. Contract awarded for A collection of approx.. 1100 FDA approved drugs in pre-dissolved 100 ul of DMSO solution for high throughput screening and high content screening. Contractor address: 211 Henderson
7/23/14 - Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
Biosceptre, the oncology company developing antibody products that target the nf-P2X 7 receptor, announces positive results from its Phase I trial to assess the safety and tolerability of BIL-010t, a topically administered, highly purified sheep antibody therapy, to treat Basal Cell Carcinoma. The Phase I trial, conducted in the US, was an open-lab
7/23/14 - Puma Bio More Than $100 After-Hours On Trial PB272; CEL-SCI Receives Regulatory Clearance To Expand Phase III Head And Neck Cancer Trial
A list of the 32 studies found for Puma Biotechnology at ClinicalTrials.gov================================= CEL-SCI Corporation announced Turkey s Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI s global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatme
7/23/14 - United States : MedImmune and Advaxis partner on immuno-oncology combination clinical trial [TendersInfo (India)]
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies. The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune s investigational anti-PD-L1...
7/23/14 - United States : TRANSTECH PHARMA announces agreement with the US FDA for neurology products for ALZHEIMER'S patients [TendersInfo (India)]
TransTech Pharma, LLC announced that it reached an agreement with the US Food and Drug Administration Division of Neurology Products, under the Special Protocol Assessment process, on the design of a single Phase 3 trial of TTP488 for the treatment of patients with mild Alzheimer s disease. A Special Protocol Assessment from the FDA is a binding ag
7/22/14 - ACT Gets FDA Date, CGIX Opens Wallet, DPRX Once Again Takes OneStep Forward
WASHINGTON- Actavis plc announced that the New Drug Application for Levosert, an investigational hormonal intrauterine contraceptive for use by women to prevent pregnancy, has been accepted for review by FDA. Actavis signed a partnership deal with Medicines360, a non-profit pharmaceutical company, for Levosert in June 2013. Anacor Pharmaceuticals I
7/22/14 - Actelion delivers strong half year operational and financial results
Actelion Pharmaceuticals Ltd/ Actelion delivers strong half year operational and financial results. ALLSCHWIL/ BASEL, SWITZERLAND- 22 July 2014- Actelion Ltd today announced its results for the first half of 2014. OPERATING HIGHLIGHTS* Opsumit- US launch momentum remains strong* Opsumit- Ten market introductions in HY 2014; filed in Japan* Selexipa
7/22/14 - Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune...
7/22/14 - Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/ 693,478. The 478 patent application includes newly allowed claims directed to compositions including those comprising a m
7/22/14 - Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
ENP Newswire- 22 July 2014. Release date- 21072014- NEW YORK- Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system and various types of cancer, today announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its dr
7/22/14 - Antares Pharma Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males
Antares Pharma, Inc. today announced that the first patient has been dosed in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot Testosterone administered subcutaneously once each week to testosterone-deficient adult males. Eamonn P. Hobbs, President and Chief Executive Officer, stated, We are very e
7/22/14 - AstraZeneca's MedImmune Teams With Advaxis For Combined Cancer Trial
LONDON- AstraZeneca PLC said Tuesday its research and development arm MedImmune has teamed up with US biotechnology company Advaxis Inc for a clinical trial combining MedImmune's MED14736 compound with Advaxis' ADSX-HPV. AstraZeneca said that preclinical evidence suggests a combined treatment could enhance overall anti-tumour response.
7/22/14 - CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey
CEL-SCI Corporation today announced that Turkey s Ministry of Health has cleared the company to begin patient enrollment in CEL-SCI s global pivotal Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine*. The Company expects to enroll patients through three clinical centers in Turkey.
7/22/14 - Clinverse, Inc. Announces Key Additions to Management Team
Clinverse, Inc., provider of the first end-to-end technology solution for automating the financial lifecycle of global clinical trials, announced the addition of Shaun Williams as Vice President, Operations and the promotion of Heather Schultz to the newly created role of Senior Vice President, Product Solutions. He brings more than 20 years of exp
7/22/14 - CORRECT: AstraZeneca's MedImmune Teams With Advaxis For Cancer Trial
LONDON- AstraZeneca PLC said Tuesday its research and development arm MedImmune has teamed up with US biotechnology company Advaxis Inc for a clinical trial combining MedImmune's MEDI4736 compound with Advaxis' ADXS-HPV. AstraZeneca said that preclinical evidence suggests a combined treatment could enhance overall anti-tumour response.
7/22/14 - Cubist Reports Second Quarter 2014 Financial Results
Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2014. CUBICIN net product revenues increased 3% to $234.7 million from $227.1 million in Q2 2013 which included a $6.6 million favorable adjustment to revenue reserves. International product revenues were $17.5 million compared to $15.0 million in Q2 2013.
7/22/14 - Cytonics Announces FDA Approval of an Investigational New Drug Application for the APIC Cell-Free System
Cytonics Corporation has announced that an Investigational New Drug application for a phase I/II clinical trial of the company's APIC Cell-Free System has been approved by the FDA. The system is indicated for the rapid preparation of concentrated protease inhibitors in plasma, specifically Alpha-2-Macroglobulin, for the treatment of mild to moderat
7/22/14 - ERYTECH Announces Enrollment of First Patient in Phase I/II Study of ERY-ASP in Acute Lymphoblastic Leukemia in the United States
ERYTECH Pharma, the French biopharmaceutical company that develops innovative tumor starvation treatments for acute leukemia and other oncology indications with unmet medical needs, announces the enrollment of the first patient in its Phase I/II study with ERY-ASP in Acute Lymphoblastic Leukemia in the United States of America.. ERY-ASP, in E
7/22/14 - FDA Grants Genentech's Avastin Priority Review In Ovarian Cancer
SOUTH SAN FRANCISCO- Genentech, a member of the Roche Group, Tuesday said the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. The designation of Priority Revie
7/22/14 - FDA Grants Genentech's Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. New treatment options are needed, said S
7/22/14 - Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma
Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the first patient has been dosed in cohort 1 of the Company's Phase 1 B clinical trial evaluating GR-MD-02 in combination with ipilimumab in patients with metastatic melanoma. Providence Portland Medic
7/22/14 - Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that the U.S. Food and Drug Administration, or the FDA, cleared Galmed's Investigational New Drug, or IND, applicatio
7/22/14 - Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects
Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/ 2 a study of GEN-003, the Company s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that rema
7/22/14 - GNW-News: Actelion delivers strong half year operational and financial results (english)
Actelion delivers strong half year operational and financial results. Actelion Pharmaceuticals Ltd/ Actelion delivers strong half year operational and financial results. ALLSCHWIL/ BASEL, SWITZERLAND- 22 July 2014- Actelion Ltd today announced its results for the first half of 2014..
7/22/14 - Halozyme Announces Resumption of Patient Enrollment, Dosing in PEGPH20 Clinical Trial
Halozyme Therapeutics, Inc. today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidas
Articles(s): 1 - 25 of 234     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415